IP Library › Granted Patent US 11,535,850
Granted Patent B2
US 11,535,850 · App. 17/581,239 · Granted Dec 27, 2022

Methods for improving the health of porcine species by targeted inactivation of CD163

Inventors: Andrew Mark Cigan (Madison, WI); Jonathan Edward Lightner (Jefferson, WI); Matthew Scott Culbertson (Wilmington, NC); William Thomas Christianson (Hendersonville, TN); Benjamin Beaton (DeForest, WI); Brian Burger (Madison, WI); Dylan Barnes (Madison, WI); Matthew Campbell (Madison, WI)
Assignee: Genus PLC
C12N15/113A01K67/0275C12N9/22C12N15/8778A01K2217/052A01K2227/108C12N2310/20C12N2320/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,535,850
App. No.
17/581,239
Granted
Dec 27, 2022
Kind
B2
Abstract

The present disclosure relates methods and compositions useful for prevention of porcine reproductive and respiratory syndrome virus (PRRSv) in animals, including animals of the species Sus scrofa . The present teachings relate to swine wherein at least one allele of a CD163 gene has been inactivated, and to specific methods and nucleic acid sequences used in gene editing to inactivate the CD163 gene. Swine wherein both alleles of the CD163 gene are inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSv). Elite lines comprising homozygous CD163 edited genes retain their superior properties.

Claims (29)

1. A genetically modified pig whose genome comprises a CD163 gene comprising the nucleic acid sequence of SEQ ID NO: 453, wherein the pig expresses CD163 protein that exhibits reduced binding to porcine reproductive and respiratory syndrome virus (PRRSV) relative to a wild-type CD163 protein.

2. A cell isolated from the genetically modified pig according to claim 1 .

3. An isolated cell line obtained from the genetically modified pig of claim 1 .

4. An isolated fibroblast cell line obtained from the genetically modified pig of claim 1 .

5. The genetically modified pig of claim 1 , wherein the genetically modified pig is heterozygous for the nucleic acid sequence of SEQ ID NO: 453.

6. A cell isolated from the genetically modified pig according to claim 5 .

7. An isolated cell line obtained from the genetically modified pig of claim 5 .

8. An isolated fibroblast cell line obtained from the genetically modified pig of claim 5 .

9. The genetically modified pig of claim 1 , wherein the genetically modified pig is homozygous for the nucleic acid sequence of SEQ ID NO: 453.

10. A cell isolated from the genetically modified pig according to claim 9 .

11. An isolated cell line obtained from the genetically modified pig of claim 9 .

12. An isolated fibroblast cell line obtained from the genetically modified pig of claim 9 .

13. A method of producing a genetically modified pig, the method comprising:

a) introducing:

i) a Cas9 protein or a nucleic acid sequence encoding a Cas9 protein;

ii) a guide RNA (gRNA) comprising the nucleic acid sequence of SEQ ID NO: 249; and

iii) a gRNA comprising the nucleic acid sequence of SEQ ID NO: 256 into an isolated pig cell;

b producing a genetically modified pig from the isolated pig cell, wherein the genetically modified pig comprises at least some cells whose genomes comprise the nucleic acid sequence of SEQ ID NO: 453 and express, CD163 protein that exhibits reduced binding to porcine reproductive and respiratory syndrome virus (PRRSV) relative to a wild-type CD163 protein.

14. The method of claim 13 , wherein the isolated pig cell is a fertilized oocyte, and further wherein the producing comprises implanting the fertilized oocyte into a surrogate mother.

15. The method according to claim 13 , further comprising breeding the genetically modified pig to a wild-type pig to create a plurality of first generation progeny.

16. The method according to claim 15 , further comprising:

breeding the plurality of first generation progeny to produce a plurality of second generation progeny.

17. The method according to claim 16 , wherein individuals from the plurality of second progeny are homozygous for the nucleic acid sequence of SEQ ID NO: 453.

18. The method according to claim 13 , wherein the isolated pig cell is a fibroblast cell.

19. A genetically modified pig produced by the method of claim 13 .

20. The method according to claim 13 , wherein the producing somatic cell nuclear transfer of the isolated pig cell or a cell derived therefrom.

21. The method according to claim 20 , further comprising implanting the pig embryo obtained from the somatic cell nuclear transfer into a surrogate mother.

22. The method according to of claim 13 , wherein the isolated pig cell is a pig zygote or embryo.

23. The method according to of claim 22 , wherein the producing comprises implanting the pig zygote or embryo into a surrogate mother.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2022
From: CIGAN, ANDREW MARK; LIGHTNER, JONATHAN EDWARD; CULBERTSON, MATTHEW SCOTT; CHRISTIANSON, WILLIAM THOMAS
To: GENUS PLC
Reel/Frame 060291/0979 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2022
From: BEATON, BENJAMIN; BURGER, BRIAN
To: GENUS PLC
Reel/Frame 060292/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2022
From: BARNES, DYLAN; CAMPBELL, MATTHEW
To: GENUS PLC
Reel/Frame 060292/0382 →
Continuity (5)
Continuation 17515139 · Oct 29, 2021
Continuation 17307369 · May 4, 2021
Provisional Application 63021370 · May 7, 2020
Provisional Application 63020128 · May 5, 2020
Related Publication 20220135976A1 · May 5, 2022
Cited By (2)
US 12,371,692 US 12,416,005